Celyad Oncology

About Celyad Oncology

Celyad Oncology is a cutting-edge biotechnology company focused on pioneering the discovery and advancement of revolutionary technologies for chimeric antigen receptor (CAR) T-cell therapies to address cancer indications and overcome limitations of current treatments.

Products & Services

CAR T-cell Therapies:Development of technology platforms and CAR T-cell candidates to target a broad range of cancer indications and address limitations of existing CAR T-cell therapies.

Specialties

Chimeric Antigen Receptor (CAR) T-cell Therapies Cancer Treatment Technologies CAR T-cell therapies cancer immunotherapy technology platforms

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Private Placement T: - FT: Private Placement	A: 540000 MR: - FA: €500,000 FAN: 540000	D: 2026-07-15 FD: 2026-07-15	2 investors
2	RT: Private Placement T: - FT: Private Placement	A: 9800000 MR: - FA: approximately EUR 9,800,000 FAN: 9800000	D: 2023-08-24 FD: 2023-08-24	3 investors

Private Placement Latest

2026-07-15

$540K

2 investors (Pro only)

Private Placement 2023-08-24

$9.8M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

D

David Georges

VP of Finance and Administration

A

An Phan

Head of Legal

H

Hannes Iserentant

Head of Intellectual Property

H

Hilde Windels

Chairwoman of the Board

M

Matt Kane

Non-Executive Director

M

Michel Lussier

Non-Executive Director

View 10 more team members with Pro

Unlock Full Team Directory

Recent News

Celyad Oncology Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised